Additional Treatments to the Local Tumour for Metastatic Prostate Cancer: Assessment of Novel Treatment Algorithms

  • Active Not Recruiting
  • Treatment
  • Interventional
  • Randomized
  • Combination Product & Procedure
  • PHASE2
  • Imperial College London
  • 18 Years -


Study Purpose

Local cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatment

Intervention

Combination Product : Standard of Care

Procedure : Minimally Invasive Ablative Therapy (MIAT)

Procedure : Radical Therapy (Prostatectomy or Radiotherapy)


Eligibility Requirements

info icon Diagnosed with prostate cancer within 6 months of screening visit

info icon Metastatic disease (Any T, Any N, M1+) of any grade, stage or Prostate Specific Antigen (PSA) level.

info icon Fit to undergo standard of care treatment for metastatic disease and both minimally invasive therapy and prostate radiotherapy/prostatectomy.

info icon Performance status 0-2

info icon Histologically proven local tumour

info icon Minimum age: 18

info icon Patient did not undergo and/or is unable to undergo standard of care baseline imaging tests for confirmation of metastatic status (CT abdomen/pelvis AND chest Xray (or CT chest) AND radioisotope bone scan (or whole body imaging such as MRI or PET imaging as alternative to all preceding scans mentioned here) AND prostate MRI.

info icon Prior exposure to long-term androgen deprivation therapy or hormonal therapy for the treatment of prostate cancer unless started within 6 months of screening visit.

info icon Prior chemotherapy or local or systemic therapy for treatment of prostate cancer (apart from ADT or hormonal therapy as outlined above)

Recruiting status

Active Not Recruiting

Estimated enrollment

433

 
Study start date

Apr 10, 2019

Study end date

Jan 31, 2027

Last updated

Mar 22, 2025

Primary purpose

Treatment

Design

Interventional

Intervention

Combination Product & Procedure

Study phase

PHASE2

Allocation

Randomized

 

Sponsor:

Imperial College London

Collaborator:

Wellcome Trust

Investigator:

Hashim U Ahmed, FRCS Urol

NCT03763253

Clinic Location Investigator Distance RECRUITING STATUS Contact